Substituted Urea Derivatives for Selective Mu Opioid Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management therapies, particularly for chronic and neuropathic pain, often fail to provide adequate relief due to tolerance, side effects, and risk of dependence, with opioids leading to respiratory depression, constipation, and other adverse effects.
Innovation Solution
Development of compounds that selectively bind to the mu opioid receptor, inducing G-protein signaling while minimizing β-arrestin recruitment, thereby reducing side effects and promoting sustained pain relief without tolerance or dependence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioids are administered to treat pain, then pain relief is achieved, but respiratory depression and other adverse effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I) that selectively target G-protein coupled receptors to produce analgesia while minimizing activation of receptors mediating respiratory depression. The compounds are engineered to have differential binding properties at various opioid receptor subtypes, achieving localized therapeutic effect with reduced systemic harm.
Solution Approach 2:
The patent employs parameter changes by modifying key molecular parameters of opioid compounds including the R1, R2, R3 substituents, and structural features at positions A and B. These parameter modifications alter the compounds' pharmacological profile to enhance pain relief while reducing adverse effects such as respiratory depression, constipation, and tolerance development.
2Reliability
If opioid doses are increased to overcome tolerance, then pain relief is maintained, but the risk of adverse side effects increases
Solution Approach 1:
The patent uses parameter changes by optimizing the molecular structure parameters of the compounds (formula I) to achieve high analgesic efficacy at low doses. The specific substituent patterns and structural features are designed to maximize therapeutic effect while minimizing the development of tolerance and reduction of side effects, allowing sustained pain relief without dose escalation.
Solution Approach 2:
The patent applies this principle by developing compounds that provide effective but transient analgesia without inducing long-term tolerance or dependence. The compounds are designed to deliver acute pain relief with minimal cumulative effects, avoiding the progressive tolerance issue that characterizes traditional opioid therapy.
3Reliability
If traditional opioids are used for chronic pain, then initial pain relief is achieved, but tolerance and dependence develop over time
Solution Approach 1:
The patent applies parameter changes by modifying the molecular structure parameters of opioid compounds to alter their pharmacokinetic and pharmacodynamic properties. The compounds in formula I are designed with specific substituent combinations that prolong effective pain relief while reducing tolerance development, extending the duration of therapeutic benefit compared to traditional opioids.
Solution Approach 2:
The patent employs dynamics by designing compounds that adapt their mechanism of action to maintain efficacy over time. The compounds dynamically interact with G-protein coupled receptors to provide sustained analgesia while minimizing the development of tolerance and dependence, allowing for long-term pain management without the progressive loss of effectiveness seen with traditional opioids.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds offer effective pain relief with reduced risk of adverse effects such as respiratory depression, constipation, and tolerance, providing a safer alternative for managing chronic and neuropathic pain.
Implementation Method 1
inducing G-protein signaling while minimizing β-arrestin recruitment
Implementation Method 2
inducing G-protein signaling while minimizing β-arrestin recruitment
Data Source
AI summary
The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.